It
is well established that African Americans respond more poorly to interferon-based
therapy compared with Caucasians. Racial differences in rates of obesity and diabetes
may contribute to differences in rates of steatosis and treatment response.
The
aim of the present study, published in the January 2007 issue of Hepatology,
was to compare rates of hepatic steatosis in African American and Caucasian American
patients with chronic genotype 1 hepatitis C who participated in a prospective
clinical trial of pegylated interferon plus ribavirin.
Liver
biopsy results were available for 194 African American and 205 Caucasian patients.
Results
61%
of the African American patients and 65% of the Caucasian patients had liver steatosis
(P = 0.38).
In
a univariate analysis, steatosis was associated with the following factors: -
HOMA-IR insulin resistance score; - body mass index; - waist circumference; -
serum triglyceride level; - aminotransferase (ALT and AST) levels; - histological
scores for liver inflammation and fibrosis.
After
adjusting for these factors, African American patients had a lower risk of steatosis
than Caucasian patients (OR 0.54; P = 0.02).
Insulin resistance but not steatosis was associated with a lower rate of sustained
virological response after adjusting for known factors that predict treatment
response (P = 0.028).
Conclusion
In
conclusion, the authors wrote, "After adjusting for the higher prevalence
of features associated with hepatic steatosis, African American patients had a
lower prevalence of hepatic steatosis than did Caucasian patients with chronic
hepatitis C, genotype 1. Insulin resistance but not steatosis was independently
associated with lower sustained virological response."
01/05/07
Reference H
S Conjeevaram, D E Kleiner, J E Everhart, and others. Race, insulin resistance,
and hepatic steatosis in chronic hepatitis C. Hepatology 45(1): 80-87.
January 2007.